meningococc
diseas
first
clinic
characteris
gaspard
vieusseux
caus
agent
identifi
anton
weichselbaum
name
diplococcu
intracellulari
menigitidi
begin
diseas
dread
epidem
natur
predilect
previous
healthi
children
adolesc
high
mortal
last
decad
centuri
concept
serum
therapi
toxinrel
bacteri
diseas
identifi
concept
appli
meningococc
diseas
therapi
independ
way
wilhelm
koll
august
von
wasserman
georg
jochmann
germani
simon
flexner
usa
result
first
success
approach
treatment
meningococc
diseas
first
three
decad
centuri
serum
therapi
standard
treatment
meningococc
diseas
advent
sulphamid
first
antibiot
serum
therapi
abandon
great
challeng
infecti
diseas
medicin
face
await
menac
futur
term
increas
antibiot
resist
emerg
new
pathogen
reemerg
old
one
without
effect
therapi
make
passiv
immunotherapi
promis
tool
acknowledg
achiev
predecessor
might
teach
us
lesson
bring
light
futur
wwwthelancetcominfect
vol
seen
stand
shoulder
giant
isaac
newton
meningococc
diseas
never
describ
ancient
time
despit
distinct
rash
substanti
proport
patient
januari
gaspard
vieusseux
gener
practition
first
clinic
characteris
meningococc
diseas
short
epidem
eaux
vive
quarter
geneva
switzerland
postmortem
examin
case
later
describ
andr
matthey
diseas
receiv
name
malign
non
contagieus
noncontagi
malign
cerebr
fever
new
epidem
diseas
describ
vieusseux
subsequ
report
medfield
usa
new
england
state
virginia
kentucki
ohio
pennsylvania
usa
canada
throughout
centuri
epi
demic
meningococc
diseas
spread
countri
europ
north
south
america
coloni
africa
western
asia
epidem
mortal
diseas
rang
case
theodor
kleb
first
observ
cocci
cerebrospin
fluid
csf
patient
die
mening
find
subsequ
confirm
mani
author
onward
diplococcu
pneumonia
albert
pneumoniekokku
consid
caus
epidem
sporad
mening
year
anton
weichselbaum
pathologist
vienna
austriahungari
studi
germ
caus
mening
found
postmortem
examin
eight
patient
die
sporad
mening
abl
cultur
diplococcu
pneumonia
two
wherea
six
patient
observ
differ
microorgan
name
diplococcu
basi
morpholog
intracellulari
basi
locat
meningitidi
due
potenti
caus
mening
bacteriolog
studi
mening
epidem
occur
led
diplococcu
intracellulari
meningitidi
establish
main
caus
epidem
cerebrospin
mening
therapeut
attempt
serum
therapi
high
fatal
meningococc
diseas
epidem
observ
centuri
meant
diseas
consid
one
worst
prognosi
compar
plagu
cholera
therefor
countless
method
test
centuri
therapeut
intent
replac
one
anoth
accord
theori
predomin
period
postul
caus
diseas
vieusseux
recommend
emet
occasion
bloodlet
lothario
danielson
elia
mann
observ
harm
effect
bloodlet
advis
administr
fowler
miner
solut
wine
wherea
nathan
strong
jr
maintain
best
treatment
nutriti
diet
stimul
medicin
alcohol
beverag
opium
either
pure
laudanum
potassium
iodid
quinin
mani
compound
extens
use
subject
heat
scientif
discuss
opium
believ
specif
remedi
meningococc
mening
stimul
properti
popular
compound
initi
use
mercuri
administ
ointment
oral
calomel
mercuri
chlorid
aim
reliev
sever
headach
patient
mening
compress
soak
cold
water
sulphur
ether
appli
head
rachi
immers
patient
two
three
time
day
warm
hot
water
likewis
recommend
none
remedi
succeed
modifi
cours
diseas
although
could
provid
symptomat
relief
end
centuri
walter
essex
wynter
alreadi
use
repeat
lumbar
punctur
treat
tubercul
mening
start
csf
drainag
whether
mean
repeat
punctur
insert
trocar
cathet
subarachnoid
lumbar
cistern
level
without
concomit
laminectomi
one
therapeut
pillar
bacteri
mening
decad
idea
reduc
pressur
csf
diminish
bacteri
load
surgic
procedur
also
use
therapeut
purpos
acut
phase
meningo
coccal
mening
includ
suboccipit
decompress
aim
ensur
perman
drainag
cisterna
magna
trepan
variou
locat
subsequ
practic
socal
intrathec
wash
advoc
done
repeat
punctur
subarachnoid
space
subsequ
instil
normal
salin
distil
water
sodium
citrat
solut
intend
therapeut
step
forward
antisept
substanc
instil
intrathec
lysol
protargol
carbol
acid
solut
flavin
eusol
hexamin
helmitol
hydrogen
peroxid
begin
centuri
colloid
silver
salvarsan
neosalvarsan
antimoni
tartrat
soamin
subcutan
inject
turpentin
consequ
format
socal
fixat
abscess
bilater
intracarotid
inject
pregl
iodin
solut
also
use
treatment
method
shown
complet
ineffect
despit
specif
success
alleg
author
emil
von
behr
kitasato
laid
foundat
serum
therapi
infecti
diseas
gener
serum
contain
antibodi
capabl
neutralis
effect
clostridium
tetani
corynebacterium
diphtheria
toxin
immunis
hors
bacteri
toxin
georg
felix
klemper
show
serum
therapi
protect
rabbit
streptococcu
pneumonia
infect
pave
way
type
treatment
develop
similar
serumbas
treatment
human
infect
april
wilhelm
koll
august
von
wassermann
figur
berlin
institut
infektionskrankheiten
royal
prussian
institut
infecti
diseas
announc
obtain
start
immunis
hors
serum
protect
guinea
pig
meningococc
diseas
basi
result
obtain
anim
experiment
recommend
use
meningococc
diseas
human
may
georg
jochmann
describ
equin
antimeningococc
serum
protect
guinea
pig
intraperiton
meningococc
infect
jochmann
work
breslau
wroclaw
presentday
poland
experi
serum
sinc
meningococc
diseas
epidem
still
persist
upper
silesia
part
poland
antimeningococc
serum
administ
patient
breslau
ratibor
result
obtain
present
intern
medicin
congress
held
munich
april
patient
ratibor
present
clinic
benefit
paper
drew
attent
prefer
intrathec
subcutan
rout
administr
simon
flexner
figur
new
york
rockefel
institut
medic
research
ny
usa
began
studi
antimeningococc
serum
therapi
independ
german
research
flexner
research
biolog
properti
meningococcu
capabl
produc
experiment
meningococc
mening
macacu
rhesu
thu
obtain
model
valid
effect
serum
flexner
immunis
two
macacu
nemestrinu
produc
homolog
serum
subsequ
experi
inject
meningococc
cultur
intrathec
ten
rhesu
five
treat
also
intrathec
previous
obtain
serum
wherea
five
anim
use
control
histor
review
control
die
four
anim
treat
homolog
antimeningococc
serum
surviv
flexner
continu
experiment
studi
immunis
hors
product
serum
intend
treatment
human
first
serum
avail
koll
wassermann
jochmann
flexner
time
antimeningococc
serum
appear
ruppel
germani
markl
austriahungari
subsequ
charl
dopter
franc
antimeningococc
serum
obtain
immunis
hors
variou
slightli
differ
method
figur
basic
serumobtain
procedur
consist
subcutan
intraven
administr
increas
dose
initi
dead
meningococci
subsequ
phase
live
organ
differ
result
base
whether
research
immunis
hors
solubl
autolyt
product
meningococc
cultur
age
strain
administ
use
strain
one
numer
patient
depend
era
success
immunis
hors
determin
differ
method
includ
opson
complement
fixat
agglutin
anim
protect
studi
immun
serum
first
observ
mening
treat
anti
meningococc
serum
obviou
intrathec
rout
administr
effect
treatment
lumbar
punctur
use
extract
volum
csf
equal
slightli
higher
volum
serum
administ
around
ml
serum
previous
heat
introduc
spinal
canal
mean
repeat
inject
use
graviti
infus
system
consist
contain
rubber
tube
equip
shutoff
valv
introduc
intrathec
serum
patient
place
trendelenburg
posit
event
block
subarachnoid
space
imposs
practis
lumbar
punctur
serum
administr
done
cistern
ventricular
level
daili
administr
serum
continu
disappear
fever
diplococci
csf
patient
mening
author
also
recommend
simultan
administr
serum
intraven
rout
high
dose
case
meningococc
sepsi
without
mening
intraven
administr
hypersensit
reaction
frequent
sideeffect
follow
administr
antimeningococc
serum
occur
case
tabl
summaris
result
treatment
antimeningococc
serum
first
epidem
use
mark
reduct
mortal
repres
serum
therapi
appar
also
soon
appreci
effect
serum
therapi
directli
proport
earli
administ
analysi
data
epidem
outlin
tabl
show
substanti
reduct
mortal
patient
treat
serum
compar
untreat
patient
howev
casecontrol
studi
rather
report
surviv
serumtr
compar
surviv
untreat
patient
meningococc
diseas
epidem
therefor
given
import
limit
studi
design
data
interpret
great
caution
notwithstand
limit
result
compel
enough
time
settl
serum
therapi
treatment
choic
meningococc
diseas
antimeningococc
serum
continu
standard
therapi
recommend
subsequ
histori
antimeningococc
serum
therapi
run
parallel
advanc
made
relat
antigen
characterist
meningococcu
final
allow
classif
serogroup
flexner
alreadi
shown
exist
case
meningococc
mening
strain
respons
shown
resist
serum
therapi
begin
serum
therapi
serum
prepar
empir
random
manner
cultur
meningococcu
isol
multipl
patient
dopter
describ
socal
parameningococci
isol
nasopharynx
individu
contact
patient
affect
meningococc
mening
morpholog
cultur
ident
classic
meningococcu
distinguish
agglutin
reaction
year
harri
elser
jame
huntoon
specifi
biochem
serolog
characterist
meningococcu
cultur
prepar
monoval
polyval
serum
clinic
use
often
sequenti
began
time
diagnosi
polyval
serum
use
first
type
causal
agent
treatment
continu
correspond
monoval
serum
case
appear
high
percentag
failur
serum
therapi
record
mortal
thu
rise
figur
similar
preserum
therapi
era
disappoint
result
attribut
fact
serum
avail
came
previou
year
fact
presum
contain
antibodi
strain
respons
defici
storag
condit
serogroupspecif
antimeningococc
serum
therefor
obtain
began
appli
lead
reduct
mortal
similar
begin
serum
therapi
era
attempt
enhanc
effect
serum
therapi
complement
fresh
human
serum
obtain
patient
individu
recov
meningococc
diseas
method
call
complement
therapi
earli
centuri
ehrlich
sidechain
theori
antibodi
format
mechan
antibodi
neutralis
toxin
induc
bacteri
lysi
help
complement
alreadi
known
serum
therapi
also
combin
bacteria
therapi
autolog
vaccin
consist
administr
intrathec
rout
subcutan
rout
csf
patient
enrich
glucos
subsequ
heat
aim
obtain
liquid
million
dead
meningococci
per
ml
newel
ferri
colleagu
isol
specif
solubl
toxin
cultur
medium
variou
kind
neisseria
meningitidi
inject
toxin
guinea
pig
rabbit
gave
rise
develop
homolog
antitoxin
two
antitoxin
combin
call
meningococc
antitoxin
antitoxin
admin
ister
intraven
intramuscularli
intrathec
monotherapi
togeth
antimeningococc
serum
although
initi
result
ferri
antitoxin
show
efficaci
standard
serum
therapi
subsequ
year
differ
observ
relat
mortal
two
therapeut
option
although
patient
treat
antitoxin
present
fewer
complic
avail
antimeningococc
serum
start
proven
therapeut
effect
meant
jochmann
subsequ
ruppel
rec
ommend
prophylact
use
close
contact
patient
meningococc
diseas
howev
measur
use
isol
case
first
evid
asymptomat
carrier
n
meningitidi
fundament
role
play
epidemiolog
chain
diseas
sophian
colleagu
flexner
colleagu
worsterdrought
kennedi
gladwin
buttl
colleagu
perrin
long
eleanor
bliss
describ
favour
experiment
result
treatment
meningococc
diseas
prontosil
ie
sulfamidochrysoidin
first
applic
sulphamid
treatment
human
meningococc
diseas
took
place
franci
schwentker
colleagu
treat
ten
patient
meningococc
mening
one
sepsi
without
mening
sulphanilamid
intrathec
subcutan
ten
patient
surviv
author
specifi
subsequ
studi
requir
defin
role
sulphanilamid
monotherapi
adjuv
serum
therapi
start
numer
studi
done
treatment
meningococc
diseas
sulphamid
good
result
obtain
endors
treatment
choic
follow
year
tabl
show
result
treatment
meningococc
diseas
sulphamid
year
follow
introduct
strain
meningococcu
variabl
degre
resist
sulphamid
isol
baltimor
md
washington
dc
usa
emanuel
schoenbach
john
phair
studi
strain
meningococcu
armi
patient
carrier
found
eight
strain
inhibit
vitro
concentr
sulphadiazin
first
epidem
due
serogroup
b
meningococcu
resist
sulphadiazin
occur
spring
us
naval
train
center
san
diego
ca
shortli
afterward
fort
ord
marina
ca
usa
anoth
epidem
meningococc
diseas
occur
also
caus
serogroup
b
meningococcu
whose
isol
resist
sulphamid
find
reproduc
shortli
civilian
popul
therefor
usa
sulphamid
ceas
treatment
choic
meningococc
diseas
start
epidem
detect
caus
sulphamideresist
n
meningitidi
mekn
morocco
paulo
brazil
epidem
caus
serogroup
c
meningococcu
resist
sulphamid
isol
geograph
dispers
sulphamid
resist
n
meningitidi
determin
generalis
abandon
sulphamid
begin
era
treatment
penicillin
david
rosenberg
phillip
arl
treat
patient
meningococc
mening
use
intrathec
penicillin
dose
unit
penicillin
everi
h
associ
concomit
administr
intramuscular
intraven
rout
one
patient
die
patient
recov
without
sequela
year
manson
mead
colleagu
treat
nine
patient
similar
dose
penicillin
surviv
despit
result
believ
treatment
sulphamid
superior
given
respons
penicillin
slower
sulphamid
carrier
statu
remain
treatment
conclud
penicillin
high
dose
least
effect
sulfisoxazol
treatment
meningococc
mening
intrathec
administr
essenti
first
seri
patient
meningococc
mening
treat
penicillin
summaris
tabl
theodor
eickhoff
maxwel
finland
isol
strain
meningococcu
minimum
inhibitori
concentr
penicillin
octob
strain
meningo
coccu
isol
madrid
minimum
inhibitori
concentr
penicillin
blood
cultur
child
affect
sepsi
mening
cure
penicillin
overal
spain
frequenc
isol
decreas
suscept
penicillin
increas
first
month
among
strain
decreas
suscept
penicillin
serogroup
c
serogroup
serotyp
subtyp
initi
shown
predomin
enid
sutcliff
report
isol
strain
meningococci
decreas
suscept
penicillin
uk
penicillin
suscept
decreas
mechan
n
meningitidi
modif
penicillin
bind
protein
except
product
strain
reduc
sensit
penicillin
bind
protein
show
affin
time
lower
penicillin
comparison
sensit
strain
alter
whatsoev
shown
permeabl
extern
membran
product
inactiv
enzym
shown
pathogen
strain
neisseria
isol
spain
although
shown
among
saprophyt
fred
mccrumb
colleagu
use
first
time
chloramphenicol
treatment
meningococc
diseas
patient
meningococc
mening
receiv
drug
oral
intraven
cure
without
sequela
howev
sinc
seriou
sideeffect
chloramphenicol
shown
form
aplast
anaemia
grey
babi
syndrom
describ
high
dose
chloramphenicol
seriou
advers
effect
limit
use
releg
secondari
role
treatment
meningococc
diseas
develop
secondgener
thirdgener
cephalosporin
yield
compound
great
spectrum
antimicrobi
activ
greater
capac
cross
bloodbrain
barrier
compar
older
antibiot
includ
penicillin
correa
colleagu
treat
meningococc
mening
cefacetril
good
therapeut
respons
sinc
excel
result
publish
treatment
meningococc
mening
secondgener
thirdgener
cephalosporin
present
empir
treatment
bacteri
mening
acquir
commun
alway
includ
thirdgener
cephalosporin
passiv
serum
therapi
activ
immunis
irv
goldschneid
colleagu
began
pivot
studi
human
immun
meningo
coccu
increas
incid
due
absenc
serum
bactericid
antibodi
furthermor
show
capsular
poli
saccharid
certain
serogroup
induc
format
protect
antibodi
diseas
due
meningococci
serogroup
follow
studi
vaccin
research
isol
purif
poli
saccharid
thu
begin
path
obtain
anti
meningococc
vaccin
monoval
c
antimeningococc
vaccin
obtain
emil
gotschlich
colleagu
base
specif
capsular
polysaccharid
sero
group
c
capabl
induc
bactericid
antibodi
serum
six
volunt
c
vaccin
first
administ
larg
scale
initi
test
us
basic
militari
train
centr
monoval
antimeningococc
vaccin
also
obtain
gotschlich
colleagu
associ
high
effect
numer
test
bival
c
anti
meningo
coccal
vaccin
compos
specif
capsular
polysaccharid
serogroup
c
becam
necessari
epidem
outbreak
occur
caus
simultan
serogroup
paulo
region
african
savannah
signific
differ
found
concentr
antibodi
induc
bival
c
vaccin
compar
induc
separ
c
vaccin
macleod
griffiss
colleagu
sever
studi
volunt
adult
result
show
immunogen
advers
effect
tetraval
vaccin
similar
present
c
bival
c
vaccin
immun
respons
serogroup
specif
howev
plain
polysaccharid
vaccin
although
effect
safe
short
term
close
commun
set
sever
shortcom
vaccin
poorli
immunogen
young
children
younger
year
elicit
immunolog
memori
ineffect
carriag
develop
conjug
vaccin
major
breakthrough
vaccinolog
contain
polysaccharid
molecul
chemic
conju
gate
tcellstimul
antigen
diphtheria
tetanu
toxoid
immunogen
children
adult
elicit
immunolog
memori
elimin
carrier
statu
therebi
make
suitabl
populationscal
intervent
monoval
conjug
serogroup
c
quadrival
conjug
meningococc
vaccin
licens
date
knowledg
last
addit
vaccin
armamentarium
meningococcu
multicompon
serogroup
b
meningococc
vaccin
immuno
genic
safe
children
older
month
adolesc
adult
data
peopl
older
year
result
clinic
trial
suggest
serogroup
b
meningococc
vaccin
like
conjug
vaccin
might
lead
herd
immun
reduc
carriag
serogroup
includ
vaccin
also
serogroup
therefor
high
popul
immun
caus
efficaci
vaccin
transmiss
coverag
achiev
might
herald
remov
meningococcu
meningococc
diseas
erad
extinct
discoveri
sulphamid
later
antibiot
subsequ
introduct
led
derelict
serum
therapi
period
year
given
new
compound
broadli
effect
fewer
sideeffect
cheaper
treatment
option
howev
field
complet
abandon
meningococc
diseas
although
greatli
restrict
experiment
research
isol
clinic
experi
passiv
antibodi
therapi
infecti
diseas
becam
limit
infect
treat
antibiot
treatment
prevent
hepat
b
viru
rabi
viru
respiratori
syncyti
viru
clostridium
tetani
clostridium
botulinum
anthrax
clostridioid
difficil
coliti
vaccinia
viru
echoviru
enteroviru
howev
loom
threat
field
infecti
diseas
made
scientif
commun
turn
sight
back
use
antibodi
therapeut
use
threat
includ
develop
multidrugresist
bacteria
limit
respons
exist
treatment
caus
broad
gener
use
antibiot
veterinari
human
medicin
accord
center
diseas
control
prevent
caus
death
europ
similar
number
usa
antibioticresist
infect
moreov
emerg
new
pathogen
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
reemerg
old
known
pathogen
without
avail
vaccin
ebola
viru
epidem
west
africa
highlight
need
new
therapeut
approach
includ
passiv
immunotherapi
furthermor
problem
encount
treat
infect
immunosuppress
patient
transplant
hivinfect
patient
show
difficult
role
antimicrobi
chemotherapi
absenc
effect
immun
revolut
technolog
develop
select
gener
purif
fulli
human
antibodi
eas
mean
produc
unlimit
suppli
homogen
monoclon
antibodi
thu
past
decad
huge
number
monoclon
antibodi
caus
dramat
effect
field
oncolog
autoimmun
diseas
allergi
bowel
inflammatori
diseas
orphan
diseas
howev
palivizumab
prevent
treatment
respiratori
syncyti
viru
bezlotoxumab
prevent
recurr
c
difficil
infect
approv
infecti
diseas
given
grow
challeng
infecti
diseas
field
new
therapeut
option
greatli
need
set
antibodi
antibodyderiv
treatment
histor
review
search
strategi
involv
review
origin
histor
record
either
journal
book
mainli
european
american
sourc
sourc
identifi
addit
record
also
search
offici
record
prussian
swiss
govern
even
nonscientif
journal
articl
record
govern
nonscientif
journal
includ
histor
review
howev
report
manuscript
record
cite
bibliographi
search
well
compil
inform
review
accur
possibl
depict
period
first
clinic
descript
meningococc
diseas
discoveri
caus
agent
evolv
way
therapi
meningococc
diseas
symptomat
period
antibiot
therapi
discoveri
vaccin
search
inher
limit
due
centuryold
data
sourc
unprecis
descript
search
pubm
googl
scholar
incept
oct
record
journal
book
term
meningococc
diseas
diplococcu
intracellulari
meningitidi
neissera
meningitid
cerebrospin
mening
epidem
mening
spot
fever
cerebrospin
fever
meningococc
mening
therapi
sulphamid
treatment
penicillin
chloramphenicol
thirdgener
cephalosporin
meningococc
vaccin
monoclon
antibodi
refer
examin
english
german
french
spanish
antibiot
antimicrobi
resist
see
http
wwwcdcgov
drugresist
histor
review
might
offer
hope
address
challeng
perhap
lesson
learn
predecessor
past
might
help
us
find
new
answer
futur
like
philosoph
georg
santayana
said
rememb
past
condemn
repeat
